1.50575

LiChrospher^® RP-select B (5 µm) HPLC Columns

L x I.D. 250 mm x 4.6 mm Hibar^® RT HPLC Column

• Sinónimos: TM=["LiChrospher"] C8 HPLC column
• UNSPSC Code: 41115709
• NACRES: SB.52
• Particle size: 5 μm
• Matrix active group: C8 (RP8), C8 bonding phase
• Pore size: 60 Å pore size
• Matrix: fully porous particle

Propiedades

• Nombre del producto: LiChrospher^® RP-select B (5µm) Hibar^® RT 250-4.6, suitable for HPLC
• material: stainless steel column
• Quality Segment: 100
• agency: suitable for USP L7
• product line: LiChrospher^®
• feature: endcapped: no
• extent of labeling: 11.5% Carbon loading
• parameter: 400 bar pressure, 60 °C max. temp.
• technique(s): HPLC: suitable, mass spectrometry (MS): suitable (Low - Medium)
• column L × I.D.: 25 cm × 4.6 mm
• surface area: 350 m²/g
• matrix: fully porous particle
• matrix active group: C8 (RP8), C8 bonding phase
• particle size: 5 μm
• pore size: 60 Å pore size
• operating pH range: 2-7.5
• separation technique: reversed phase, supercritical fluid (SFC)
• storage temp.: no temp limit

Descripción

General description

HPLC column

LiChrospher^® RP-select B is a versatile traditionally produced spherical silica gel carriers with reversed phase properties and with the hydrophobicity of a C-8 phase. This carrier is very well suited for the separation of basic compounds, but with still good properties for the determination of neutral and acidic compounds. This sorbent is packed into a Hibar 100-4.6 HPLC column. For mounting of a LiChroCART 4-4 guard column, the guard column holder 1.51487 has to be used.

Application

• Simultaneous quantification of delta-9-THC, THC-acid A, CBN and CBD in seized drugs using HPLC-DAD: This study utilizes high-performance liquid chromatography with diode-array detection (HPLC-DAD), employing a LiChrospher^® RP-select B column to effectively separate and quantify cannabinoids in forensic samples, highlighting its application in legal and forensic settings (Ambach et al., 2014).


• Structural characterization of stress degradation products of Darunavir: Employing LC-MS/MS alongside HPLC, this research underscores the utility of the LiChrospher^® RP-select B column in the stability analysis of HIV medications, crucial for ensuring drug safety and efficacy (Rao et al., 2014).


• RP-HPLC separation and characterization of unknown impurities of Darunavir: This study demonstrates the column′s role in identifying and quantifying impurities in HIV-protease inhibitors, contributing to the pharmaceutical industry′s quality control measures (Nageswara Rao et al., 2013).


• Quantification of pralidoxime in urine by ion pair chromatography: The LiChrospher^® RP-select B column is applied in a biomedical context to monitor therapeutic agents in clinical settings, supporting patient treatment regimes (John et al., 2012).


• Liquid chromatography/electrospray tandem mass spectrometry method for determination of cefuroxime: This analytical method facilitates the study of pharmacokinetics in clinical pharmacology, using the LiChrospher^® RP-select B column for precise drug monitoring in plasma (Partani et al., 2010).

Analysis Note

Pressure: ≤ 90 bar
Theoretical Plates (N/m) (Toluene): ≥ 50000
Symmetry (Toluene): 0.8 - 1.4
Capacity factor (Toluene): 1.0 - 2.0

Legal Information

Hibar is a registered trademark of Merck KGaA, Darmstadt, Germany

LiChrospher is a registered trademark of Merck KGaA, Darmstadt, Germany